Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1145-1154 , August 2010

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma

  • Sally Arai

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • Corresponding Author InformationCorrespondence and reprint requests: Sally Arai, MD, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305.
    • ,
  • Renee Letsinger

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Ruby M. Wong

      Affiliations

    • Department of Health Research and Policy, Division of Biostatistics, Stanford University Medical Center, Stanford, California
    • ,
  • Laura J. Johnston

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Ginna G. Laport

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Robert Lowsky

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • David B. Miklos

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Judith A. Shizuru

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Wen-Kai Weng

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Philip W. Lavori

      Affiliations

    • Department of Health Research and Policy, Division of Biostatistics, Stanford University Medical Center, Stanford, California
    • ,
  • Karl G. Blume

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Robert S. Negrin

      Affiliations

    • Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Sandra J. Horning

      Affiliations

    • Division of Medical Oncology, Stanford University Medical Center, Stanford, California

Received 31 January 2010 ,Accepted 22 February 2010.

  • Image Result

    Survival curves for the entire group of 92 patients. Freedom from progression (FFP) at 2 years, 71% (CI 61%-81%). Event-free survival (EFS) at 2 years, 67% (CI 57%-77%). Overall survival (OS) at 2 yea

    Survival curves for the entire group of 92 patients. Freedom from progression (FFP) at 2 years, 71% (CI 61%-81%). Event-free survival (EFS) at 2 years, 67% (CI 57%-77%). Overall survival (OS) at 2 years, 83% (CI 75%-91%). Event-free survival (EFS) at 2 years was 67% (CI 57%-77%), and freedom from progression (FFP) at 2 years was 71% (CI 61%-81%).

  • Image Result
    (A) FFP in 92 patients according to number of risk factors. 0 (n = 24), 1 (n = 37), 2 (n = 23), 3 (n = 8). (B) FFP according to induction failure (IF) versus induction response (non-IF). Induction fai

    (A) FFP in 92 patients according to number of risk factors. 0 (n = 24), 1 (n = 37), 2 (n = 23), 3 (n = 8). (B) FFP according to induction failure (IF) versus induction response (non-IF). Induction failure (n = 36), induction response (n = 56). (C) FFP according to presence of B symptoms at relapse (n = 39) versus absence of B symptoms at relapse (n = 53).

  • Image Result
    (A) FFP in 77 patients according to pretransplant PET status. PET negative (n = 48), PET positive (n = 29). (B) FFP in patients who are PET positive, symptomatic (n = 15), PET positive, asymptomatic (

    (A) FFP in 77 patients according to pretransplant PET status. PET negative (n = 48), PET positive (n = 29). (B) FFP in patients who are PET positive, symptomatic (n = 15), PET positive, asymptomatic (n = 14), PET negative, symptomatic (n = 19), and PET negative, asymptomatic (n = 29). Three degrees of freedom log rank test for equality over 4 groups, P < .0001. Pairwise significant differences: between PET+ Bsx+ and PET+Bsx−, P = .004; between PET+Bsx+ and PET−Bsx+, P < .0001; between PET+Bsx+ and PET−Bsx−, P < .0001.

 Financial disclosure: See Acknowledgments on page 1152.

PII: S1083-8791(10)00095-9

doi: 10.1016/j.bbmt.2010.02.022

Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1145-1154 , August 2010

Article Tools

* Image Usage & Resolution